Luke Nathaniel Walker's most recent trade in Zentalis Pharmaceuticals Inc was a trade of 14,200 Common Stock done at an average price of $1.8 . Disclosure was reported to the exchange on Jan. 31, 2025.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
Zentalis Pharmaceuticals Inc | Luke Nathaniel Walker | Director | Purchase of securities on an exchange or from another person at price $ 1.76 per share. | 31 Jan 2025 | 14,200 | 86,681 | - | 1.8 | 24,966 | Common Stock |
Context Therapeutics Inc | Luke Nathaniel Walker | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Sep 2024 | 19,315 | 19,315 | - | - | Stock Option (right to buy) | |
Zentalis Pharmaceuticals Inc | Luke Nathaniel Walker | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 May 2024 | 72,481 | 72,481 | - | 0 | Common Stock | |
Harpoon Therapeutics Inc | Luke Nathaniel Walker | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2024 | 115,000 | 135,000 (0%) | 0% | 0 | Common Stock |